- Home
- UHS vs MRNA Comparison
UHS vs MRNA Comparison
Compare UHS & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UHS
- MRNA
- Stock Information
- Founded
- UHS 1978
- MRNA 2010
- Country
- UHS United States
- MRNA United States
- Employees
- UHS N/A
- MRNA N/A
- Industry
- UHS Hospital/Nursing Management
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- UHS Health Care
- MRNA Health Care
- Exchange
- UHS Nasdaq
- MRNA Nasdaq
- Market Cap
- UHS 10.0B
- MRNA 13.4B
- IPO Year
- UHS N/A
- MRNA 2018
- Fundamental
- Price
- UHS $165.48
- MRNA $32.15
- Analyst Decision
- UHS Buy
- MRNA Hold
- Analyst Count
- UHS 15
- MRNA 20
- Target Price
- UHS $222.07
- MRNA $46.76
- AVG Volume (30 Days)
- UHS 965.4K
- MRNA 8.5M
- Earning Date
- UHS 07-28-2025
- MRNA 08-01-2025
- Dividend Yield
- UHS 0.48%
- MRNA N/A
- EPS Growth
- UHS 39.27
- MRNA N/A
- EPS
- UHS 18.95
- MRNA N/A
- Revenue
- UHS $16,460,285,000.00
- MRNA $3,177,000,000.00
- Revenue This Year
- UHS $9.37
- MRNA N/A
- Revenue Next Year
- UHS $5.27
- MRNA $10.04
- P/E Ratio
- UHS $8.73
- MRNA N/A
- Revenue Growth
- UHS 9.61
- MRNA N/A
- 52 Week Low
- UHS $152.33
- MRNA $23.15
- 52 Week High
- UHS $243.25
- MRNA $125.68
- Technical
- Relative Strength Index (RSI)
- UHS 43.14
- MRNA 53.69
- Support Level
- UHS $152.33
- MRNA $33.35
- Resistance Level
- UHS $174.38
- MRNA $34.70
- Average True Range (ATR)
- UHS 5.85
- MRNA 1.33
- MACD
- UHS -1.04
- MRNA -0.15
- Stochastic Oscillator
- UHS 40.25
- MRNA 26.96
About UHS Universal Health Services Inc.
Universal Health Services Inc owns and operates acute care hospitals, behavior health centers, surgical hospitals, ambulatory surgery centers, and radiation oncology centers. The firm operates in two segments: Acute Care Hospital Services and Behavioral Health Services. The company generates the majority of its revenue from the Acute Care Hospital Services segment. The Acute Care Hospital Services segment includes the firm's acute care hospitals, surgical hospitals, and surgery and oncology centers.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.